Trials / Unknown
UnknownNCT04445311
Ivermectin in Treatment of COVID-19
Use of Ivermectin as a Therapeutic Option for Patients With COVID-19
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Zagazig University · Other Government
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivermectin | 3 successive days ttt of ivermectin started within 48 hours of symptoms |
Timeline
- Start date
- 2020-05-31
- Primary completion
- 2020-07-30
- Completion
- 2020-08-15
- First posted
- 2020-06-24
- Last updated
- 2020-06-24
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04445311. Inclusion in this directory is not an endorsement.